Albemarle (NYSE:ALB) Given New $119.00 Price Target at Royal Bank Of Canada

Albemarle (NYSE:ALB) had its price objective dropped by analysts at Royal Bank Of Canada from $129.00 to $119.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the specialty chemicals company’s stock. Royal Bank Of Canada‘s price target would indicate a potential upside of 20.68% from the stock’s current price.

Several other analysts have also weighed in on ALB. Weiss Ratings lowered shares of Albemarle from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 23rd. UBS Group cut their target price on shares of Albemarle from $175.00 to $150.00 and set a “buy” rating on the stock in a research note on Monday, October 5th. Citigroup decreased their price target on shares of Albemarle from $175.00 to $125.00 and set a “buy” rating for the company in a research note on Thursday, October 22nd. Zacks Research lowered shares of Albemarle from a “hold” rating to a “strong sell” rating in a report on Friday, October 9th. Finally, Argus cut their price objective on shares of Albemarle from $230.00 to $135.00 and set a “buy” rating on the stock in a research report on Wednesday, October 7th. Fifteen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $177.64.

Albemarle Trading Up 0.2%

Shares of NYSE ALB traded up $0.24 during midday trading on Friday, reaching $98.61. The stock had a trading volume of 1,084,834 shares, compared to its average volume of 2,469,517. The firm has a market cap of $11.64 billion, a price-to-earnings ratio of 23.77, a price-to-earnings-growth ratio of 0.57 and a beta of 1.34. Albemarle has a twelve month low of $89.77 and a twelve month high of $221.00. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.35 and a current ratio of 2.09. The company’s 50 day moving average price is $108.33 and its 200 day moving average price is $148.24.

Albemarle (NYSE:ALB) last posted its quarterly earnings data on Wednesday, November 4th. The specialty chemicals company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. The company had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.52 billion. Albemarle had a net margin of 10.40% and a return on equity of 15.23%. Albemarle’s revenue for the quarter was up 18.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.19) earnings per share. As a group, sell-side analysts expect that Albemarle will post 11.15 EPS for the current year.

Institutional Investors Weigh In On Albemarle

Several hedge funds and other institutional investors have recently made changes to their positions in ALB. Point Windward Advisors Inc. boosted its stake in Albemarle by 43.3% during the 3rd quarter. Point Windward Advisors Inc. now owns 15,488 shares of the specialty chemicals company’s stock valued at $1,638,000 after purchasing an additional 4,678 shares during the last quarter. Everest Financial Group LLC increased its holdings in Albemarle by 33.5% during the 3rd quarter. Everest Financial Group LLC now owns 3,861 shares of the specialty chemicals company’s stock worth $408,000 after purchasing an additional 968 shares in the last quarter. Eurizon Capital SGR S.p.A. raised its stake in shares of Albemarle by 8,337.1% in the third quarter. Eurizon Capital SGR S.p.A. now owns 436,618 shares of the specialty chemicals company’s stock worth $46,185,000 after purchasing an additional 431,443 shares during the last quarter. CENTRAL TRUST Co raised its stake in shares of Albemarle by 4,516.9% in the third quarter. CENTRAL TRUST Co now owns 21,007 shares of the specialty chemicals company’s stock worth $2,222,000 after purchasing an additional 20,552 shares during the last quarter. Finally, Three Bridge Wealth Advisors LLC purchased a new stake in shares of Albemarle in the third quarter worth approximately $45,000. 92.87% of the stock is owned by institutional investors.

Key Stories Impacting Albemarle

Here are the key news stories impacting Albemarle this week:

• Positive Sentiment: Albemarle reported Q3 adjusted earnings of $2.58 per share and revenue of $1.55 billion, both above analyst estimates. Revenue rose 18.8% year over year, and the company swung to a profit from a loss a year earlier. Reports attributed the earnings improvement to higher lithium prices, which also supported stronger cash flow. Article: ALB Q3 Earnings Beat Estimates on Higher Lithium Pricing
• Positive Sentiment: Scotiabank maintained a Sector Outperform rating and a $190 price target, forecasting EPS of $11.64 for FY2026 and $14.15 for FY2027—above the cited $11.15 current-year consensus estimate. Those projections point to potential earnings growth, though they are analyst forecasts rather than company guidance.
• Negative Sentiment: Barclays lowered its price target to $95 from $109 and kept an Equal Weight rating, implying downside from the cited share price. The reduced target signals a more cautious view and may limit enthusiasm following the earnings report. Barclays ratings

About Albemarle

Albemarle Corporation (NYSE: ALB) is a global specialty chemicals company headquartered in Charlotte, North Carolina. The company develops, manufactures, and markets engineered chemicals used in energy storage, transportation, refining, pharmaceuticals, agriculture, consumer products, and other industrial applications.

Albemarle is one of the world’s major producers of lithium and supplies lithium compounds, including lithium carbonate and lithium hydroxide, for use in rechargeable batteries for electric vehicles, portable electronics, and grid energy-storage systems.